What happened
Veru (NASDAQ: VERU), an oncology-focused biotech, saw its share price leap by over 20% on Tuesday, crushing not only the top stock market indexes, but also many peers in its sector. The reason why was clear: The company received an important regulatory nod for one of its key pipeline projects.
So what
In a press release published on Monday, Veru announced that the Food and Drug Administration (FDA) has granted Fast Track designation for the phase 3 registration program of its enobosarm. This is a selective androgen receptor agonist, administered orally, that targets certain forms of breast cancer.
Image source: Getty Images.
Veru quoted its CEO, Mitchell Steiner, as saying the regulator's move "underscores the urgent need for new, novel, targeted therapies for this important patient population suffering from this aggressive disease."
The FDA grants Fast Track designation to pipeline treatments that target serious illnesses, and/or could potentially "fill an unmet medical need," in the agency's words.
Now what
Breast cancer certainly falls into these categories. As Veru notes pointedly, it's the most common form of cancer diagnosed in women; the company quoted a statistic that an estimated one in eight women will develop it at some point in their lives. It's little wonder, then, that investors are getting sharply more bullish on the stock.
Zooming out a bit, Veru isn't just a one-trick biotech. The company does good business with its one commercialized product, the FC2 women's condom from its Female Health Company unit. It's also attracted notice for its VERU-111, an experimental antiviral that has done well in clinical trials targeting COVID-19.
10 stocks we like better than Veru, Inc
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Veru, Inc wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of January 10, 2022
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
